CL2017000118A1 - Métodos y composiciones para tratar desórdenes relacionados con el vih - Google Patents

Métodos y composiciones para tratar desórdenes relacionados con el vih

Info

Publication number
CL2017000118A1
CL2017000118A1 CL2017000118A CL2017000118A CL2017000118A1 CL 2017000118 A1 CL2017000118 A1 CL 2017000118A1 CL 2017000118 A CL2017000118 A CL 2017000118A CL 2017000118 A CL2017000118 A CL 2017000118A CL 2017000118 A1 CL2017000118 A1 CL 2017000118A1
Authority
CL
Chile
Prior art keywords
compositions
methods
related disorders
treating hiv
hiv
Prior art date
Application number
CL2017000118A
Other languages
English (en)
Inventor
Celia Dominguez
Ignacio Muñoz-Sanjuan
Leticia Toledo-Sherman
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55079070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of CL2017000118A1 publication Critical patent/CL2017000118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>METODO PARA EL TRATAMIENTO DEL TRASTORNO RELACIONADO CON VIH EN UN SUJETO CON VIH QUE COMPRENDE LA ADMINISTRACIÓN COMPLEMENTARIA DE UN COMPUESTO DERIVADO DEL ÁCIDO 6-(FENIL)PIRIMIDIN-4-CARBOXÍLICO; Y COMPOSICIÓN QUE COMPRENDE UN AGENTE ANTIVIRAL Y DICHO COMPUESTO.</p>
CL2017000118A 2014-07-17 2017-01-17 Métodos y composiciones para tratar desórdenes relacionados con el vih CL2017000118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462025840P 2014-07-17 2014-07-17

Publications (1)

Publication Number Publication Date
CL2017000118A1 true CL2017000118A1 (es) 2017-10-20

Family

ID=55079070

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000118A CL2017000118A1 (es) 2014-07-17 2017-01-17 Métodos y composiciones para tratar desórdenes relacionados con el vih

Country Status (23)

Country Link
US (1) US10258621B2 (es)
EP (1) EP3169684B1 (es)
JP (1) JP2017520610A (es)
KR (1) KR20170026633A (es)
CN (2) CN106715421A (es)
AP (1) AP2017009724A0 (es)
AU (1) AU2015289492B2 (es)
BR (1) BR112017000922A2 (es)
CA (1) CA2955379C (es)
CL (1) CL2017000118A1 (es)
CO (1) CO2017001447A2 (es)
CR (1) CR20170061A (es)
EA (1) EA034528B1 (es)
EC (1) ECSP17010817A (es)
ES (1) ES2747633T3 (es)
IL (1) IL250114B (es)
MX (1) MX2017000779A (es)
PE (1) PE20170770A1 (es)
PH (1) PH12017500110A1 (es)
SG (1) SG11201700341PA (es)
SV (1) SV2017005357A (es)
UA (1) UA120856C2 (es)
WO (1) WO2016011316A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2018039521A1 (en) * 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
EP3927710A4 (en) * 2019-03-08 2022-12-21 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE
WO2023010061A1 (en) * 2021-07-27 2023-02-02 University Of Miami Nanoparticles and uses thereof for treatment of human immunodeficiency virus
CN114601832A (zh) * 2021-12-01 2022-06-10 南方医科大学 犬尿喹啉酸在制备改善hiv-1相关神经认知功能障碍药物中的应用

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707560A (en) 1970-10-05 1972-12-26 Pfizer Certain 4-amino-6-aryl-pyrimidines
US3908012A (en) 1970-10-05 1975-09-23 Pfizer Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators
FR2204406A1 (en) 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
US3950525A (en) 1973-06-19 1976-04-13 Pfizer Inc. Relaxation of smooth muscle in a mammal
US3935202A (en) 1974-03-18 1976-01-27 American Home Products Corporation 3-(4-biphenylylcarbonyl)propionamido cephalosporin derivatives
US4634689A (en) 1985-10-31 1987-01-06 Schering Corporation Phosphinylalkanoyl imino acids
DE3609596A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
EP0288575A4 (en) 1986-10-27 1990-10-10 Yoshitomi Pharmaceutical Industries, Ltd. Piperazine compounds and their medicinal use
ZW21687A1 (en) 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
JPH01113377A (ja) 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
MX16687A (es) 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
US5102904A (en) 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
AU644159B2 (en) 1990-05-17 1993-12-02 Novartis Ag 2-anilino-4-cyanopyrimidine derivatives
DE4103695A1 (de) 1991-02-07 1992-08-13 Basf Ag Oximether und diese enthaltende fungizide
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
JPH0741459A (ja) 1993-07-29 1995-02-10 Sumitomo Pharmaceut Co Ltd 新規エラスターゼ阻害剤
ES2147210T3 (es) 1993-12-03 2000-09-01 Hoffmann La Roche Derivados de acido acetico como medicamentos.
US5338739A (en) 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
DE4430639A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
BR9611723A (pt) 1995-11-17 1999-06-01 Bayer Ag Bifenil éter-oxazolinas
CZ287868B6 (en) 1995-12-22 2001-02-14 Warner Lambert Co Aromatic keto-acids and their derivatives functioning as inhibitors of matrix metalloproteinases
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
JP2002514179A (ja) 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼの阻害剤としてのビフェニル酪酸およびその誘導体
CA2263886A1 (en) 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
DE69727695T2 (de) 1996-12-17 2005-02-10 Warner-Lambert Co. Llc Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
DE69836422T2 (de) 1997-02-19 2007-06-14 Berlex, Inc., Richmond N-heterocyclische derivate als nos inhibitoren
US5925639A (en) 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6399612B1 (en) 1997-10-06 2002-06-04 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO1999021583A1 (en) 1997-10-29 1999-05-06 Warner-Lambert Company Method of inhibiting metastases of cancer cells
AU751701B2 (en) 1997-12-23 2002-08-22 Warner-Lambert Company Ace inhibitor-MMP inhibitor combinations
US6169103B1 (en) 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
SK16412000A3 (sk) 1998-05-11 2001-08-06 Takeda Chemical Industries, Ltd. Deriváty kyseliny oxyiminoalkánovej
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
HUP0104060A3 (en) 1998-09-25 2002-04-29 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors, process for their preparation and medicaments containing them
JP4183350B2 (ja) 1998-10-28 2008-11-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェニルピロリジノン誘導体
US6541521B1 (en) 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
EP1227081A4 (en) 1999-10-29 2004-08-11 Takeda Chemical Industries Ltd PROCESS FOR THE PREPARATION OF OXYMINOALKANOIC ACID DERIVATIVES
AU1303201A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Alkoxyiminoalkanoic acid derivatives
CN1423566A (zh) 1999-11-10 2003-06-11 武田药品工业株式会社 体重增加抑制剂
GB0003671D0 (en) 2000-02-17 2000-04-05 Univ Cardiff Diphenyl-substituted lower alkanes
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2002215218A1 (en) 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Isoxazole derivatives
KR20030068189A (ko) 2000-12-21 2003-08-19 글락소 그룹 리미티드 마크롤라이드계 항생제
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
JP2002241358A (ja) 2001-02-15 2002-08-28 Nippon Soda Co Ltd オキシム基を有する化合物及び殺虫・殺ダニ剤
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
EP1394147A4 (en) 2001-06-04 2007-10-24 Eisai R&D Man Co Ltd CARBOXYLENE DERIVATIVE AND A SALT OR AN ESTER CONTAINING MEDICINE
EP1411930B1 (en) 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
US6552188B2 (en) 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
JP4303109B2 (ja) 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK &amp; CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
JP2005535710A (ja) 2002-08-09 2005-11-24 トランス　テック　ファーマ，インコーポレイテッド アリールおよびヘテロアリール化合物ならびに凝固を調節する方法
AU2003266528A1 (en) 2002-09-20 2004-04-08 Takeda Pharmaceutical Company Limited Cyclic amine compound, process for producing the same, and use
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US20040209897A1 (en) 2002-12-20 2004-10-21 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US7427632B2 (en) 2002-12-30 2008-09-23 Eli Lilly And Company Factor Xa inhibitors
EP1601799A4 (en) * 2003-03-12 2007-06-06 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-ASSOCIATED DISEASES USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735 , 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
AU2003902860A0 (en) 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
CN1566065A (zh) 2003-06-27 2005-01-19 中国医学科学院药物研究所 α位杂原子取代的γ芳基丁本酮酸衍生物及其制法和其药物组合物与用途
SE0301963D0 (sv) 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
MXPA06001002A (es) 2003-07-25 2006-04-11 Amgen Inc Piridonas y pirimidinonas sustituidas con propiedades antiinflamatorias.
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
WO2005040135A1 (ja) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
CN1890223A (zh) 2003-10-31 2007-01-03 神经能质公司 辣椒素受体促效剂
JP2007524682A (ja) 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
AU2005228417A1 (en) 2004-03-26 2005-10-13 Cytokine Pharmasciences, Inc. Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
JP4809339B2 (ja) 2004-06-28 2011-11-09 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン誘導体
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
KR20070045272A (ko) 2004-08-27 2007-05-02 아스텔라스세이야쿠 가부시키가이샤 2-페닐피리딘 유도체
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1820795A4 (en) 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2457901A1 (en) 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
CA2611002A1 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic .beta. cell proliferation
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
WO2007017289A2 (en) 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
CA2630233A1 (en) 2005-12-05 2007-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087637A2 (en) 2006-01-26 2007-08-02 Washington State University Research Foundation Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP1992361B1 (en) 2006-02-24 2012-05-02 Astellas Pharma Inc. Remedy or preventive for digestive ulcer
JP2007230963A (ja) 2006-03-03 2007-09-13 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
GB0614579D0 (en) * 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
PE20080540A1 (es) 2006-08-10 2008-06-08 Glaxo Group Ltd Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
CN101511796B (zh) 2006-09-05 2012-05-09 协和发酵麒麟株式会社 咪唑衍生物
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20080077419A1 (en) 2006-09-27 2008-03-27 Santiago Pamela M System And Method For Training Employees Of An Organization To Align Their Job Activities To Achieving The Organization's Strategic Objectives
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
RU2009117701A (ru) 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
WO2008095852A1 (en) 2007-02-08 2008-08-14 Respiratorius Ab Bronchorelaxing arylamides
LT3150586T (lt) * 2007-02-23 2020-03-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
DE112008000841T5 (de) 2007-03-29 2010-02-11 Sumitomo Chemical Company, Limited Verbindung, photoelektrischer Wandler und photoelektrochemische Zelle
WO2008121877A2 (en) 2007-04-02 2008-10-09 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
EP2002834A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
PE20091309A1 (es) 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2009132238A2 (en) * 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
JP2009280521A (ja) 2008-05-22 2009-12-03 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
JP2011184298A (ja) 2008-06-02 2011-09-22 Sanwa Kagaku Kenkyusho Co Ltd 新規化合物及びその医薬用途
JP2011527677A (ja) 2008-07-08 2011-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｈｅ−１阻害剤として有用なピロリジニル及びピペリジニル化合物
RS53688B9 (sr) * 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
WO2010011302A1 (en) 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
RS53019B (en) 2008-07-25 2014-04-30 H. Lundbeck A/S DERIVATIVES OF ADAMANTYL DIAMIDE AND THEIR USE
CA2732806A1 (en) * 2008-08-04 2010-02-11 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010017132A1 (en) 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2739058A1 (en) 2008-10-15 2010-04-22 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
MX2011004958A (es) 2008-11-13 2011-05-30 Bayer Cropscience Ag Derivados de (piridil)-azinilamina sustituidos como fungicidas.
RS53941B1 (en) 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
US8415378B2 (en) 2009-04-07 2013-04-09 Astrazeneca Ab Isoxazol-3(2H)-one analogs as therapeutic agents
AU2010243353B2 (en) 2009-04-30 2014-09-11 Astex Therapeutics Limited Imidazole derivatives and their use as modulators of Cyclin dependent Kinases
US20120041009A1 (en) 2009-05-18 2012-02-16 Sumitomo Chemical Company, Limited Pyrimidine compound and its use in pest control
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
TWI423962B (zh) 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
AU2011207229B2 (en) 2010-01-25 2015-02-12 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112012021498B8 (pt) 2010-02-27 2020-04-14 Bayer Ip Gmbh ariltriazolonas ligadas a bisaril e seu uso
TWI535442B (zh) * 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
PT2588475E (pt) 2010-07-02 2015-09-08 Gilead Sciences Inc Inibidores de cinase reguladora dos sinais da apoptose
EP3590925B1 (en) 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
EP2649065A1 (en) 2010-12-09 2013-10-16 Amgen Inc. Bicyclic compounds as pim inhibitors
EP2736337A4 (en) 2011-07-28 2014-12-17 Chdi Foundation Inc CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
US9428464B2 (en) * 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
CN104244939A (zh) 2012-04-05 2014-12-24 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
EP3049389B1 (en) 2013-09-26 2019-08-07 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2016536350A (ja) 2013-09-26 2016-11-24 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法

Also Published As

Publication number Publication date
EP3169684B1 (en) 2019-06-26
CA2955379A1 (en) 2016-01-21
MX2017000779A (es) 2017-07-27
BR112017000922A2 (pt) 2018-01-16
CA2955379C (en) 2022-12-13
EP3169684A4 (en) 2018-02-21
AP2017009724A0 (en) 2017-01-31
CN114588157A (zh) 2022-06-07
CN106715421A (zh) 2017-05-24
SG11201700341PA (en) 2017-02-27
KR20170026633A (ko) 2017-03-08
ECSP17010817A (es) 2017-03-31
EA034528B1 (ru) 2020-02-17
US10258621B2 (en) 2019-04-16
AU2015289492A1 (en) 2017-02-02
IL250114A0 (en) 2017-03-30
PH12017500110A1 (en) 2017-05-29
JP2017520610A (ja) 2017-07-27
EP3169684A1 (en) 2017-05-24
CR20170061A (es) 2017-07-17
UA120856C2 (uk) 2020-02-25
EA201790147A1 (ru) 2017-07-31
SV2017005357A (es) 2017-07-14
PE20170770A1 (es) 2017-07-04
AU2015289492B2 (en) 2020-02-20
IL250114B (en) 2019-06-30
US20170209440A1 (en) 2017-07-27
CO2017001447A2 (es) 2017-07-19
ES2747633T3 (es) 2020-03-11
WO2016011316A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2018000429A1 (es) Moduladores de la expresión de kras
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
EA201890204A1 (ru) Антибактериальные соединения
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201791182A1 (ru) Новые производные 2&#39;- и/или 5&#39;-аминокислотных эфиров фосфороамидатов 3&#39;-дезоксиаденозина в качестве противораковых соединений
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
AR107990A1 (es) Formulación granulada de 5-metil-1-fenil-2-(1h)-piridona y método para elaborarla
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX370628B (es) Composiciones y metodos para tratar las espinillas.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
CL2016002754A1 (es) Dispositivo de tratamiento y procedimiento de tratamiento para el decapado y fosfatado de piezas de metal
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide